NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, ...

Lone Pine Capital's 13F portfolio value increased slightly from $13.41B to $13.47B. Check out the new stakes and significant ...

Eli Lilly and Company (NYSE:LLY) is a leading multinational pharmaceutical company that develops and markets healthcare products across various therapeutic areas. Its products range from ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Successful investing means ignoring hype and sticking to quality-forever holdings. Read more about two dividend stocks that ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.